Role of immunohistochemistry and flow cytometry in minimal residual disease detection in NPM1-mutated AML

Int J Lab Hematol. 2022 Apr;44(2):e76-e78. doi: 10.1111/ijlh.13722. Epub 2021 Oct 27.

Authors

Nidhi Aggarwal¹, Erin L J Alston², Geraldine S Pinkus², Olga K Weinberg³

Affiliations

¹ Department of Pathology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
² Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Department of Pathology, UT Southwestern Medical Center BioCenter, Dallas, Texas, USA.

PMID: 34704364
DOI: 10.1111/ijlh.13722

No abstract available

Keywords: NPM1; Immunohistochemistry; minimal residual disease.

Publication types

Letter

MeSH terms

Flow Cytometry
Humans
Immunohistochemistry
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / genetics
Mutation
Neoplasm, Residual / diagnosis
Neoplasm, Residual / genetics
Nuclear Proteins / genetics
Prognosis

Substances

Nuclear Proteins